Bristol-Myers Squibb to Acquire Celgene

On Jan. 22, 2018, Celgene announced they had acquired Juno Therapeutics. Juno’s CAR-T, JCAR017, looks very promising in CLL and is very similar to the CAR-T that I took in my successful clinical trial. One year later, on Jan. 3, 2019, Bristol-Myers Squibb announced plans to acquire Celgene. Here is a link to press coverage: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-acquire-celgene-create-premier-innovative

New Test Approved for Payment by Medicare for Measuring Minimal Residual Disease (MRD) in Chronic Lymphocytic Leukemia or CLL
January 12, 2020

The FDA announced Breakthrough Therapy Designation (BTD) for acalabrutinib (Calquence) as a single agent to treat chronic lymphocytic leukemia (CLL)
August 15, 2019

Shuttering of the Biden Cancer Initiative
August 5, 2019

Approval of a biosimilar for Rituximab
July 29, 2019

AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL)
May 29, 2019

May 15, 2019: FDA approved venetoclax in combination with obinutuzumab for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
May 20, 2019